Biotech is not for the faint of heart. About 90% of drugs and therapies tested fail to make it to market. Even drugs with promising phase 2 data are up against huge odds of failure -- as Incyte(NASDAQ:INCY) shareholders were reminded of all too well today.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,